



Egyptian Society of Cardiology  
The Egyptian Heart Journal

www.elsevier.com/locate/ehj  
www.sciencedirect.com



CASE REPORT

# Angiotensin II type 1 receptor (A1166C) gene polymorphism and essential hypertension in Egyptian population



Marium M. Shamaa<sup>a,\*</sup>, Hosny Fouad<sup>b</sup>, Medhat Haroun<sup>c</sup>, Lobna Abu Shamaa<sup>d</sup>

<sup>a</sup> Dept. of Pharmacology, Faculty of Pharmacy, University of Pharos, Egypt

<sup>b</sup> Dept. of Pharmacology, Faculty of Pharmacy, University of Alexandria, Egypt

<sup>c</sup> Dept. of Biotechnology, Institute of Graduate Studies and Research, University of Alexandria, Egypt

<sup>d</sup> Dept. of Immunology, Institute of Medical Research, University of Alexandria, Egypt

Received 22 February 2015; accepted 20 February 2016

Available online 25 March 2016

## KEYWORDS

Essential hypertension;  
*ATRI* (*A1166C*) polymorphism;  
*Angiotensin II type 1 receptor* gene

**Abstract** The pathogenesis of essential hypertension (EH) is affected by genetic and environmental factors. Mutations in hypertension-related genes can affect blood pressure (BP) via alteration of salt and water reabsorption by the nephron. The genes of the renin-angiotensin system (RAS) have been extensively studied because of the well documented role of this system in the control of BP. It has been previously shown that *Angiotensin II type 1 receptor* (*ATRI*) gene polymorphism could be associated with increased risk of EH. So, in the current study, we evaluated the frequency of *ATRI* (*A1166C*) polymorphism in relation to EH in a group of Egyptian population. The study population included 83 hypertensive patients and 60 age and sex matched healthy control subjects. Restriction fragment length polymorphism – Polymerase chain reaction (RFLP – PCR) was used for the analysis of *A1166C* polymorphism of *ATRI* genes in peripheral blood samples of all patients and controls. The results revealed that there was a positive risk of developing EH when having the T allele whether in homozygous or heterozygous state. From this work, it was concluded that there was an association between *ATRI* (*A1166C*) gene polymorphism and the risk of developing EH. © 2016 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Essential hypertension is a major risk factor for several cardiovascular diseases. It is a complex trait resulting from the interactions of multiple genetic and environmental factors.

\* Corresponding author at: 6th AbuNawas St. in front of Arab Academy of Science and Technology, Miami, Alexandria, Egypt. Tel.: +20 35488324, mobile: +20 127537121.

Peer review under responsibility of Egyptian Society of Cardiology.

<http://dx.doi.org/10.1016/j.ehj.2016.02.004>

1110-2608 © 2016 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Moreover, not only genetic but also epigenetic inheritance plays a significant role. One can speculate that hypertension develops as a consequence of “errors” in the well-coordinated regulatory systems of blood pressure.<sup>1</sup> This common disease-common variant concept suggests that the genetic heterogeneity underlying hypertension susceptibility could be relatively small. Therefore, it makes sense that variation in genes related to hypertension should be studied.<sup>2</sup> In recent years, the research is directed toward analyses of the disease on genetic level and explanation of the genetic bases of this

disorder. Development of powerful and sensitive molecular techniques has resulted in widespread endeavors to dissect the genetic factors and their molecular defects accounting for hypertension in various populations. Today, the state-of-the-art approach toward the diagnosis of primary hypertension involves analysis of the genetic bases for the disorder.<sup>3</sup>

The renin-angiotensin system (RAS) is a group of related hormones that act together to regulate BP by maintaining vascular tone and the balance of water and sodium. Angiotensin II type 1 receptor (AT1R) is among the components that are involved in the activation/effector cascade of the RAS. Ang II is a potent vasoconstrictor that exerts most of its known cellular actions through the Ang II type 1 receptor (AT1R). The Ang II AT1R receptor is a membrane bound G protein-coupled receptor that mediates the vasoconstrictive effects of Ang II.<sup>4,5</sup> Although many polymorphisms of the *AT1R* gene (accession number: P30556) have been identified, the (*A1166C*) polymorphism has been the most extensively studied. The (*A1166C*) polymorphism is in a non-coding region of the gene, and therefore the amino acid sequence of the receptor is not altered. In theory, associations with *ACE* genotype may be due to functional variants in nearby loci, and/or related genetic polymorphism.<sup>6</sup>

The *AT1R* gene (*A1166C*) polymorphism has been shown to be associated with oxidative stress in heart failure patients.<sup>7</sup> It has been also shown to interrupt the ability of microRNA-155 to attenuate translation, resulting in augmented *AT1R* expression.<sup>8</sup> This suggests a potential functional mechanism by which the 3'UTR *A1166C* polymorphism can lead to increased oxidative stress and the development of cardiovascular diseases. Taken together, these findings are interpreted to support the hypothesis that *AT1R* (*A1166C*) polymorphism is related to augmented angiotensin II activity and important clinical end points, including EH and cardiovascular disease.<sup>9</sup> Genetic polymorphisms in components of the RAS including *AT1R* (*A1166C*) are suggested to be associated with the pathogenesis of EH. However, the obtained results are still debated.<sup>4</sup>

The analysis of RAS related genetic polymorphism of patients having EH has been carried out in Egyptian population on a limited scale. So, this study aimed to determine the association of genetic polymorphisms of the Angiotensin II type 1 receptor (*A1166C*) gene polymorphism with EH in a cohort of genetically homogenous EH patients and normotensive controls (case-control study).

## 2. Materials and methods

The current study included 83 EH patients (55 males and 28 females) with mean age of  $53.5 \pm 7.4$  years old. Also 60 healthy subjects (32 males and 28 females) matching in age and sex ( $51.3 \pm 8.8$  years old) were included as control group. The patients were selected from the outpatient clinic of the Cardiology Department, General Alexandria University Hospital, during the period between 2009 and 2010. A written consent was obtained from all subjects accepting to participate in the study for both the clinical part and the genetic study. All subjects under study were subjected to thorough history taking and clinical examination with special emphasis on BP and BMI. Peripheral blood samples were collected from all subjects and routine investigations were done including FBS, lipid

profile (total cholesterol, LDL - ch, HDL - ch and triglycerides) and renal function tests (serum urea and creatinine).

Essential hypertension was diagnosed in individuals with a systolic blood pressure (SBP) > 140 mmHg and/or a diastolic blood pressure (DBP) > 90 mmHg or in those currently receiving anti-hypertensive therapy. Secondary forms of hypertension were excluded based on clinical history and laboratory investigations. The normotensive controls were healthy individuals with a negative history of hypertension and with a SBP < 140 mmHg and DBP < 90 mmHg measured on three separate occasions, and also all study subjects were non-diabetic with normal renal functions.

### 2.1. Genotyping

DNA samples were isolated from peripheral blood lymphocytes by the standard phenol extraction method. The *AT1R* (*A1166C*) polymorphism was detected by RFLP PCR using the following primers: 5'- GCA GCA CTT CAC TAC CAA ATG GGC - 3' as forward primer and 5' CAG GAC AAA AGC AGG CTA GGG AGA - 3' as reverse primer. The RFLP PCR reaction for amplification of *AT1R* gene was carried out as follows: 15  $\mu$ l PCR master mix, 3  $\mu$ l DNA template (0.5  $\mu$ g), forward and reverse primers 1  $\mu$ l each (30 pmole) and completed to a final volume of 30  $\mu$ l with 10  $\mu$ l nuclease free water. PCR condition consisted of an initial denaturation at 95 °C for 5 min, followed by 35 cycles of denaturation at 94 °C for 1 min, annealing at 55 °C for 1 min, and elongation at 72 °C for 1 min, with a final extension at 72 °C for 7 min. Amplification resulted in a 255-bp product. Then the PCR product was digested with the restriction enzyme *Bacillus* species (*BsuRI*) (FastDigest® HaeIII (*BsuRI*), Fermentas Chemical Co., Germany, Cat#FD0154). Electrophoresis on a 3% (w/v) agarose gel containing 0.5  $\mu$ g/ml ethidium bromide (Sigma-Aldrich, St. Louis, USA) and UV transillumination were used for analysis.


Statistical Analysis was carried out using SPSS version 15.0 software and the following tests were used for data analysis: Chi squared ( $\chi^2$ ) test, Monte Carlo Probability (MCP) and Fisher's Exact Probability (FEP) were used for analysis of categorical data, *T*-test was used for comparison between means, and Odds ratio (OR) was used for the measurement of association.

## 3. Results


The results showed that there was a highly statistically significant difference ( $p < 0.001$ , and  $p < 0.001$ ) in both the systolic BP ( $145.28 \pm 7.0$  mmHg) and the mean diastolic BP ( $91.2 \pm 2.15$  mmHg) of hypertensive patients when compared to their corresponding values ( $117.33 \pm 4.27$  mmHg and  $79.17 \pm 3.46$  mmHg), respectively of normotensive subjects (control group).

Genotyping of *AT1R* (*A1166C*) polymorphism, detected after PCR amplification and *BsuRI* digestion, yielded two bands of 231 and 24 bp in the presence of the restriction site (*C* allele) and only one band of 255 bp in the absence of the restriction site (*A* allele). Heterozygotes (*AC*) produce two bands of 255 and 231 bp<sup>10</sup> (Figs. 1 and 2).

The results revealed that the frequency of the *AC* genotype was significantly ( $\chi^2 = 10.612^*$ ,  $p = 0.005$ ) increased in



**Figure 1** Agarose gel (3%) electrophoresis for RFLP digested PCR products. Lane 1: 100 bp base pair marker. Lane 2: undigested PCR product of a patient with AA genotype (255 bp) (positive control). Lane (3, 5, 7): unrestricted fragments of PCR products of patients with AA genotype (255 bp). Lane 6: restricted PCR product of a patient with AC genotype (255, 231 bp). Lane 4: restricted PCR product of a patient with CC genotype (231 bp).



**Figure 2** Polyacrylamide gel electrophoresis of *ATR1* (*A1166C*) polymorphism bands after digestion by *Bsu* RI, lane 1: bp marker (100 bp). Lanes 2, 3, 5 and 6: AA homozygote. Lane 7: CC homozygote and lane (4, 8): AC heterozygote.

**Table 1** The frequency of *ATR1* (*A1166C*) polymorphic genotypes in normotensive subjects (control) and hypertensive patients.

	Control ( <i>n</i> = 60)		Patients ( <i>n</i> = 83)		$\chi^2$ ( <i>p</i> )
	No.	%	No.	%	
<i>ATR1</i> genotypes					
AA	53	88.3	55	66.3	9.175* (0.002)
AC	7	11.7	21	25.3	4.111* (0.043)
CC	0	0.0	7	8.4	FEp = 0.022*
$\chi^2$ ( <i>p</i> )	10.612 (0.005*)				

$\chi^2$ : Chi square test.  
FEp: *p* value for Fisher Exact test.  
\* Statistically significant at  $p \leq 0.05$ .

hypertensive patients. Furthermore, there was a positive risk of developing EH when having the *CC* and *AC* genotypes and the results were highly statistically significant (OR = 2.89,  $p = 0.022$ ) (Tables 1 and 3).

The frequency of C allele was significantly ( $\chi^2 = 12.930^*$ ,  $p < 0.001$ ) increased in hypertensive patients. Furthermore,

**Table 2** The frequency of *ATR1* A and C alleles in normotensive subjects (control) and hypertensive patients.

	Control ( <i>n</i> = 60)		Patients ( <i>n</i> = 83)		$\chi^2$ ( <i>p</i> )
	Freq.	%	Freq.	%	
<i>ATR1</i> alleles					
A	113	94.16	131	78.92	12.930* (<0.001)
C	7	5.83	35	21.08	

$\chi^2$ : Chi square test.  
FEp: *p* value for Fisher Exact test.  
\* Statistically significant at  $p \leq 0.05$ .

there was a positive risk of developing EH when having the C allele whether in homozygous or heterozygous state and the results were highly statistically significant (OR = 4.313,  $p < 0.001$ ) (Tables 2 and 4).

#### 4. Discussion

Cardiovascular diseases are rapidly emerging as a major health concern in most developing countries, including Egypt, and

**Table 3** The risk of having *ATRI* (*A1166C*) polymorphism in relation to essential hypertension.

	Control (n = 60)		Patients (n = 83)		OR	95% CI (LL – UL)	$\chi^2$ (p)
	No.	%	No.	%			
<i>ATRI</i> genotypes							
AA®	53	88.3	55	66.3	–	–	–
AC	7	11.7	21	25.3	2.891*	1.14–7.36	5.227* (0.022)
CC	0	0.0	7	8.4	–	–	FEp = 0.015*

FEp: p value for Fisher Exact test.  
 $\chi^2$ : Chi square test.  
 \* Statistically significant at  $p \leq 0.05$ .

**Table 4** The risk of having C allele in relation to essential hypertension.

	Control (n = 60)		Patients (n = 83)		OR	95% CI (LL – UL)	$\chi^2$ (p)
	Freq.	%	Freq.	%			
<i>ATRI</i> alleles							
A®	113	94.16	131	78.92	–	–	12.930*
C	7	5.83	35	21.08	4.313*	1.84–10.09	(<0.001)

$\chi^2$ : Chi square test  
 \* Statistically significant at  $p \leq 0.05$ .

hypertension is one of the major preventable causes of morbidity and mortality from cardiovascular disease. Very recently, Arafa and Ez-elarab<sup>11</sup> calculated the prevalence of prehypertension and hypertension based on the data of 6671 individuals from the EDHS 2008. The prevalence of prehypertension and hypertension in Egypt were 57.2% and 17.6%, respectively. Only 25.2% of the population had normal BP levels of < 120/80 mmHg.

The analysis of *ATRI* (*A1166C*) gene polymorphism of patients having EH has been carried out in Egyptian population on a limited scale. The potential role of the *ATRI* gene in predisposition to hypertension is controversial. Since Bonnardeaux et al.,<sup>12</sup> previously reported higher prevalence of the C1166 allele among hypertensive than among normotensive subjects, a large number of studies have explored the relationship between *ATRI* gene polymorphism and HT. In the current study, the percentage of the AC and CC genotypes was significantly more frequent in hypertensive patients than in the control group ( $p < 0.001$ ). Moreover, the C allele was the risk allele for hypertension where the study subjects carrying C allele were at more than sevenfold higher risk for hypertension (OR = 4.313,  $p < 0.001$ ).

The results of this study were in accordance with studies that were conducted in Budapest, Hungary,<sup>13</sup> in French women,<sup>14</sup> in Serbia,<sup>15</sup> in Japanese subjects,<sup>16</sup> Han Chinese<sup>17</sup> and in Tunisian population.<sup>18</sup> On the contrary, there was no significant association between the A1166C polymorphism and hypertension in a German population,<sup>19,20</sup> on non-Caucasian populations<sup>21</sup> and in Hispanic population<sup>22</sup>.

## 5. Conclusion and recommendations

The present study provided an additional observation concerning *ATRI* (*A1166C*) polymorphic genotypes in a sample of Egyptian patients with EH. From this study it was concluded that:

1. The frequency of C allele was higher in hypertensive patients (22%) as compared to control subjects (6%). On the contrary, the A allele was less frequent in hypertensive patients (79%) as compared to control subjects (94%).
2. Homozygosity for the *ATRI* C allele was a risk factor for EH. Moreover, the presence of *ATRI* C allele, whether in homozygous or heterozygous state, was a risk factor for EH.

It is recommended that:

1. Future studies should investigate the influence of genetic polymorphisms of the *ATRI* (*A1166C*) polymorphic genotypes on response to anti-hypertensive therapy.
2. Future studies should evaluate the association of the *ATRI* (*A1166C*) polymorphic genotypes in other human diseases affected by alterations in the RAS.

## Conflict of interest

The authors declare that there are no conflict of interests.

## References

1. Kunes J, Zicha J. The interaction of genetic and environmental factors in the etiology of hypertension. *Physiol Res* 2009;**58**: S33–41.
2. Balam-ortiz E, Esquivel-villarreal A, Alfaro-ruiz L, Carrillo K, Elizalde A, Gil T, et al. Variants and haplotypes in angiotensinogen gene are associated with plasmatc angiotensinogen level in Mexican population. *Am J Med Sci* 2011;**342**:205–11.
3. Elzanaty F, Way A. Egypt Demographic and Health Survey 2008. Recommended citation. Ministry of Health El-Zanaty and Associates and Macro International. Chapter 17. *Adult Health Issues* 2009;**11**:228–35.
4. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin – angiotensin – aldosterone system modulation and emerging device-based approaches. *Eur Heart J* 2011;**32**:2739–47.
5. Santos RA, Ferreira AJ, Simões E, Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1–7)-Mas axis. *Exp Physiol* 2008;**93**:519–27.
6. Puthuchery Z, Skipworth JR, Rawal J, Loosemore M, Van Someren K, Montgomery HE. The ACE gene and human performance: 12 years on. *Sports Med* 2011;**41**:433–48.
7. Cameron VA, Mocatta TJ, Pilbrow AP, Frampton CM, Troughton RW, Richards AM, et al. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. *Hypertension* 2006;**47**:1155–61.
8. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M, et al. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. *J Biol Chem* 2007;**282**:24262–9.
9. Poirier O, Georges JL, Ricard S, Arveiler D, Ruidavets JB, Luc G, et al. New polymorphisms of the angiotensin II type 1 receptor



- gene and their associations with myocardial infarction and blood pressure: the ECTIM study. Etude Cas-Témoins de l'Infarctus du Myocarde. *J Hypertens* 1998;**16**:1443–7.
10. Buraczynska M, Ksiazek P, Drop A, Zaluska W, Spasiewicz D, Ksiazek A. Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. *Nephrol Dial Transplant* 2006;**21**:979–90.
  11. Arafa NA, Ez-elarab HS. Epidemiology of prehypertension and hypertension among Egyptian adults. *Egypt J Commun Med* 2011;**29**:1–18.
  12. Bonnardeaux A, Davies E, Jeunmaitre X. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. *Hypertension* 1994;**24**:63–9.
  13. Szombathy T, Szalai C, Katalin B, Palicz T, Romics L, Császár A. Association of angiotensin II type 1 receptor polymorphism with resistant essential hypertension. *Clin Chim Acta* 1998;**269**:91–100.
  14. Tíret L, Blanc H, Ruidavets JB. Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study. *J Hypertens* 1998;**16**:37–44.
  15. Stanković A, Zivkovic M, Glisić S, Alavantić D. Angiotensin II type 1 receptor gene polymorphism and essential hypertension in Serbian population. *Clin Chim Acta* 2003;**327**:181–5.
  16. Kobashi G, Hata A, Ohta K, Yamada H, Kato EH, Minakami H, et al. A1166C variant of angiotensin II type 1 receptor gene is associated with severe hypertension in pregnancy independently of T235 variant of angiotensinogen gene. *J Human Genet* 2004;**49**:182–6.
  17. Niu W, Qi Y, Hou S, Zhai X, Zhou W, Qiu C. Haplotype-based association of the renin-angiotensin-aldosterone system genes polymorphisms with essential hypertension among Han Chinese: the Fangshan study. *J Hypertens* 2009;**27**:1384–91.
  18. Mehri S, Mahjoub S, Hammami S, Zaroui A, Frih A, Betbout F. Renin-angiotensin system polymorphisms in relation to hypertension status and obesity in a Tunisian population. *Mol Biol Rep* 2011;**23**:309–16.
  19. Schmidt S, Beige J, Walla-Friedel M. A polymorphism in the gene for the angiotensin II type 1 receptor is not associated with hypertension. *J Hypertens* 1997;**15**:1385–8.
  20. Morisawa T, Kishimoto Y, Kitano M, Kawasaki H, Hasegawa J. Influence of angiotensin II type 1 receptor polymorphism on hypertension in patients with hypercholesterolemia. *Clin Chim Acta* 2001;**304**:91–7.
  21. Takami S, Katsuya T, Rakugi H. Angiotensin II type 1 receptor gene polymorphism is associated with increase of left ventricular mass but not with hypertension. *Am J Hypertens* 1998;**11**:316–21.
  22. Bautista LE, Vargas CI, Oróstegui M, Gamarra G. Population-based case-control study of renin-angiotensin system genes polymorphisms and hypertension among Hispanics. *Hypertens Res* 2008;**31**:401–8.